Automating NGS sample preparation to accelerate microbiome research Microbiome research often involves complex workflows and ...

Takara Bio USA, Inc. today announced the launch of its CSP Program and announced the certification of Admera Health on the ...

Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Association of ...

As next-generation sequencing (NGS) costs gradually decline, the Food and Drug Administration’s (FDA) Division of Antiviral Products (DAVP) anticipates that more companies will make the switch to NGS ...

Next-generation sequencing (NGS) was developed at the turn of the millennium, and the first complete sequence of the human genome was achieved in 2022. Recent technological developments now allow us ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

NGS continually delivers breakthroughs in genomics, and to do so, it relies on the crucial step of sample preparation. Complex and expensive workflows are significant challenges. At Revvity, we are ...

The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of ...

Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...